Literature DB >> 11155092

Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men.

K W Smith1, H A Feldman, J B McKinlay.   

Abstract

To design a self-administered screening questionnaire to inform men about their risk for testosterone deficiency. The screener was developed in two phases. First was a construction phase in which relevant risk factors and a scoring algorithm were defined from multiple logistic regression analyses of survey data. In the second phase, the screener's accuracy (based on sensitivity, specificity, and Receiver Operating Characteristic (ROC) curves) was tested using patients from a primary care clinic. All subjects provided blood samples for endocrine testing. Survey data from 1660 men aged 40-79 years participating in the Massachusetts Male Ageing Study (MMAS) were analysed in the first phase. The clinic sample consisted of 304 men aged 40-79 years presenting at a large Massachusetts primary health care clinic for routine check-ups or minor medical problems. The primary outcome was testosterone deficiency, defined as serum total testosterone below 12.1 nmol/l. Self-reported variables considered as potential risk factors included age, obesity, chronic diseases, health behaviour, the Jackson dominance scale, and symptoms of stress. The prevalence of testosterone deficiency was 20.4% in the MMAS and 42.1% in the clinic sample. An eight-item screener was developed based on age, body mass index, diabetes, asthma, headaches, sleep patterns, dominance preferences, and smoking status. The screener performed significantly better than chance in identifying men with low testosterone levels; the area under the ROC curve was 0.66 in the MMAS sample and 0.67 in the clinic sample. The self-scored screener developed in this study reliably detects men at risk of hypogonadism. The screener encourages at risk men to seek professional evaluation of their testosterone levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155092     DOI: 10.1046/j.1365-2265.2000.01152.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  27 in total

Review 1.  [Symptoms or complaints in the aging male--which questionnaires are available?].

Authors:  M E Beutel; H Schneider; W Weidner
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 3.  How to recognize late-onset hypogonadism in men with sexual dysfunction.

Authors:  Giovanni Corona; Giulia Rastrelli; Linda Vignozzi; Edoardo Mannucci; Mario Maggi
Journal:  Asian J Androl       Date:  2012-01-30       Impact factor: 3.285

Review 4.  [Diagnosis of the "aging male"--what is recommended?].

Authors:  V S Lenk
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

Review 5.  Andropause: is the emperor wearing any clothes?

Authors:  S H Tariq; M T Haren; M J Kim; J E Morley
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

6.  Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells.

Authors:  Shaletha Holmes; Babak Abbassi; Chang Su; Meharvan Singh; Rebecca L Cunningham
Journal:  Endocrinology       Date:  2013-08-19       Impact factor: 4.736

7.  Effects of Oxidative Stress and Testosterone on Pro-Inflammatory Signaling in a Female Rat Dopaminergic Neuronal Cell Line.

Authors:  Shaletha Holmes; Meharvan Singh; Chang Su; Rebecca L Cunningham
Journal:  Endocrinology       Date:  2016-05-11       Impact factor: 4.736

8.  [Clinical symptoms of hypogonadism after radical prostatectomy].

Authors:  D Ridderskamp; M Zellner
Journal:  Urologe A       Date:  2011-04       Impact factor: 0.639

9.  Hypogonadism: Easy to define, hard to diagnose, and controversial to treat.

Authors:  Joshua Sterling; Aaron M Bernie; Ranjith Ramasamy
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

10.  Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta.

Authors:  Rebecca L Cunningham; Andrea Giuffrida; James L Roberts
Journal:  Endocrinology       Date:  2009-10-16       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.